Developer docs
API playgroundTry for free, no card

Search company profiles

Longeviti

Full company profile

uuid0000fwv

Namestring
Longeviti
Legal namestring
Longeviti Neuro Solutions, LLC
Websiteurl
longeviti.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Longeviti Neuro Solutions, LLC is a privately held neurotechnology and medical device company founded in 2016 and headquartered in Baltimore, Maryland. The company develops and commercializes the ClearFit platform, a portfolio of FDA-cleared sonolucent cranial implants that allow ultrasound waves to pass through the skull, enabling real-time, radiation-free post-operative brain imaging at the bedside. Its product line includes ClearFit OTS (off-the-shelf sterilized implants in multiple shapes and curvatures), ClearFit Patient Specific (custom implants for cranial reconstruction), InvisiShunt, and InvisiLead (low-profile implants that accommodate neurosurgical hardware such as shunts while restoring skull contour). The company has also launched ClearFit AI, an AI-enabled imaging platform integrated with handheld ultrasound transducers from Clarius Mobile Health and GE Healthcare for point-of-care neurosurgical monitoring.

Longeviti serves a specialized neurosurgical end market — primarily neurosurgeons, neurointensivists, neuro-radiologists, and the hospitals and surgical centers where complex brain surgery is performed. Use cases include post-operative monitoring for hydrocephalus, tumor recurrence, hemorrhage, midline shift, EC-IC bypass patency, and pseudomeningocele, all of which historically require CT imaging, patient transport, and radiation exposure. The ClearFit platform addresses these pain points by enabling bedside ultrasound through the implant itself, reducing transport risk and radiation burden while supporting faster clinical decisions. The company has secured an ICD-10-PCS procedure code (XNR80D9) for the implant category, supporting hospital reimbursement.

The business operates an enterprise field-sales model targeting neurosurgery departments and hospitals, supported by a Sales Representative Portal for CT uploads and order placement, alongside medical education services (ClearFit Imaging Workflow training, neurosonography courses, phantom training, and site visits at Centers of Excellence). Revenue is generated primarily through one-time sales of the implants to hospitals, complemented by professional services revenue from training programs. The company has raised approximately $33.5M cumulatively across multiple SEC-exempt offerings (2019-2025), most recently receiving a $10M strategic capital infusion from Soleus Capital in August 2025. The board and leadership team includes former Stryker, K2M, and T. Rowe Price executives, and the company is led by CEO and co-founder Jesse Christopher with Dr. David Langer (Chair of Neurosurgery, Lenox Hill Hospital) as Chief Medical Officer.

Short descriptiontext

Longeviti Neuro Solutions is a Baltimore-based medical device company that develops and sells FDA-cleared sonolucent cranial implants (ClearFit platform) enabling real-time, radiation-free post-operative ultrasound brain imaging for neurosurgeons and hospitals performing complex brain surgery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cranial implants, neurosurgical devices, sonolucent implants, post-operative imaging, brain surgery platforms
Industry3 codes
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurosurgical Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales (Implants)
TypeOne Time License
Description

Sale of FDA-cleared cranial implants including ClearFit OTS, ClearFit Patient Specific, InvisiShunt, and InvisiLead products. These are一次性医疗器械产品 sold to hospitals and surgical centers for neurosurgical procedures.

longeviti.com
2Medical Education Services
TypeProfessional Services
Description

Provision of medical education including ClearFit imaging workflow training, neurosonography courses, phantom training, and site visits to Centers of Excellence. These services support clinical adoption and proper usage of ClearFit implants.

longeviti.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1ClearFit OTS (Off-the-Shelf) implants - standardized sizes
ModelOne time/ perpetual licenseBilling cadenceOne time/ perpetual license
Notes

Pricing not publicly disclosed; medical device sold through standard hospital procurement channels

longeviti.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ClearFit OTS
Description

FDA-cleared off-the-shelf cranial implants that enable real-time ultrasound imaging at the bedside or clinic

longeviti.com
+3 more records
Core offering1 text field

Longeviti designs, manufactures, and commercializes FDA-cleared sonolucent cranial implants under its ClearFit® platform, allowing real-time post-operative ultrasound imaging of the brain at the bedside without radiation exposure. The portfolio includes ClearFit OTS off-the-shelf implants, ClearFit Patient Specific custom implants, InvisiShunt and InvisiLead low-profile implants for neurosurgical device accommodation, and AI-powered handheld ultrasound transducers integrated with Clarius and GE systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • ICD-10-PCS Code: XNR80D9 assigned for Ultrasound Penetrable replacement cranial plate
Product overview1 text field

Longeviti Neuro Solutions is a neurotechnology company that has developed an innovative platform ecosystem for complex brain surgery. The core offering is the ClearFit® platform, which includes ClearFit® OTS (off-the-shelf) and ClearFit® Patient Specific cranial implants—sonolucent implants that enable real-time post-operative ultrasound imaging of the brain, eliminating the need for radiation-based imaging and enabling bedside monitoring. The platform also includes InvisiShunt® and InvisiLead, which are low-profile cranial implants that integrate seamlessly with the skull for neurosurgical device accommodation. The ClearFit AI™ component powers handheld ultrasound transducers from Clarius and GE, providing AI-enabled imaging capabilities. All products work together to provide comprehensive neurosurgical solutions that return patients to anatomical normalcy while providing functional neurotechnology.

Product and service1 record
1ClearFit® OTS (Off-the-Shelf) Cranial Implants
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierStrategicTypeTechnology or Integration
Description

GE Healthcare provides high-resolution, AI-enabled ultrasound systems that integrate with Longeviti's ClearFit platform, enabling real-time post-operative brain imaging through sonolucent cranial implants.

Strategic tierStrategicTypeTechnology or Integration
Description

Clarius provides wireless, high-resolution handheld ultrasound systems integrated with Longeviti's ClearFit AI platform for point-of-care brain imaging through cranial implants.

3Strategic Collaborators (Partners for Advancing Neurosurgery Technology)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Longeviti partners with leading organizations to advance technology in neurosurgery. The company has a network of strategic collaborators including medical technology companies, healthcare institutions, and research organizations (specific partners listed via logos on About page).

longeviti.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Integra LifeSciences is a leading neurosurgical and CMF (craniomaxillofacial) implant manufacturer with overlapping cranial plate, dural repair, and neurosurgery portfolios, making it the closest direct competitor to Longeviti in cranial reconstruction hardware.

TypeBroad incumbent
Description

Stryker operates one of the largest neurosurgery, spine, and CMF businesses globally, including cranial implants and instrumentation, and Longeviti's Chair Tim Scannell is the former Stryker President & COO, indicating direct overlap in neurosurgical implant categories.

TypeBroad incumbent
Description

DePuy Synthes is the dominant CMF and neurosurgical implant franchise within J&J MedTech, offering cranial plates, fixation, and neurosurgical tools that compete head-to-head with Longeviti's ClearFit and InvisiShunt implants in hospital tenders.

TypeDirect peer
Description

KLS Martin specializes in CMF surgery implants and distraction devices, directly comparable to Longeviti's patient-specific cranial implant offering, particularly in reconstructive and trauma cranial procedures.

TypeBroad incumbent
Description

Medtronic's Neurosurgery business includes shunts and cranial fixation products that overlap with Longeviti's InvisiShunt and ClearFit offerings, and the company competes with Longeviti in the same neurosurgery hospital call points.

TypeBroad incumbent
Description

Aesculap, the surgical division of B. Braun, offers CMF implants and neurosurgical instrumentation, competing with Longeviti across cranial reconstruction and neurosurgical workflows in hospitals globally.

TypeEmerging player
Description

Hyperfine makes the FDA-cleared Swoop portable MRI for point-of-care brain imaging at the bedside, an emerging alternative imaging modality to Longeviti's ClearFit ultrasound-based bedside monitoring in neuro-ICU and post-operative settings.

TypeEmerging player
Description

NovaSignal develops AI-enabled transcranial Doppler ultrasound for automated brain blood flow assessment, overlapping with Longeviti's ClearFit AI platform in point-of-care neurovascular imaging through the skull.

TypeEmerging player
Description

Viz.ai applies AI to neuroimaging workflows for stroke and other neurological conditions, overlapping with Longeviti's ClearFit AI strategy of embedding software intelligence into neurosurgical and neuro-imaging workflows.

TypeBroad incumbent
Description

Penumbra is a neurovascular and neurosurgery-focused medical device company with overlapping presence in neurosurgical hospital accounts and adjacent technology to Longeviti's neuro-implant and AI workflow platform.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Longeviti

Neurosurgical Medical Deviceslongeviti.com

Longeviti Neuro Solutions is a Baltimore-based medical device company that develops and sells FDA-cleared sonolucent cranial implants (ClearFit platform) enabling real-time, radiation-free post-operative ultrasound brain imaging for neurosurgeons and hospitals performing complex brain surgery.

What Longeviti does

Longeviti Neuro Solutions, LLC is a privately held neurotechnology and medical device company founded in 2016 and headquartered in Baltimore, Maryland. The company develops and commercializes the ClearFit platform, a portfolio of FDA-cleared sonolucent cranial implants that allow ultrasound waves to pass through the skull, enabling real-time, radiation-free post-operative brain imaging at the bedside. Its product line includes ClearFit OTS (off-the-shelf sterilized implants in multiple shapes and curvatures), ClearFit Patient Specific (custom implants for cranial reconstruction), InvisiShunt, and InvisiLead (low-profile implants that accommodate neurosurgical hardware such as shunts while restoring skull contour). The company has also launched ClearFit AI, an AI-enabled imaging platform integrated with handheld ultrasound transducers from Clarius Mobile Health and GE Healthcare for point-of-care neurosurgical monitoring.

Longeviti serves a specialized neurosurgical end market — primarily neurosurgeons, neurointensivists, neuro-radiologists, and the hospitals and surgical centers where complex brain surgery is performed. Use cases include post-operative monitoring for hydrocephalus, tumor recurrence, hemorrhage, midline shift, EC-IC bypass patency, and pseudomeningocele, all of which historically require CT imaging, patient transport, and radiation exposure. The ClearFit platform addresses these pain points by enabling bedside ultrasound through the implant itself, reducing transport risk and radiation burden while supporting faster clinical decisions. The company has secured an ICD-10-PCS procedure code (XNR80D9) for the implant category, supporting hospital reimbursement.

The business operates an enterprise field-sales model targeting neurosurgery departments and hospitals, supported by a Sales Representative Portal for CT uploads and order placement, alongside medical education services (ClearFit Imaging Workflow training, neurosonography courses, phantom training, and site visits at Centers of Excellence). Revenue is generated primarily through one-time sales of the implants to hospitals, complemented by professional services revenue from training programs. The company has raised approximately $33.5M cumulatively across multiple SEC-exempt offerings (2019-2025), most recently receiving a $10M strategic capital infusion from Soleus Capital in August 2025. The board and leadership team includes former Stryker, K2M, and T. Rowe Price executives, and the company is led by CEO and co-founder Jesse Christopher with Dr. David Langer (Chair of Neurosurgery, Lenox Hill Hospital) as Chief Medical Officer.

Longeviti firmographics

Firmographics
Name
Longeviti
Legal name
Longeviti Neuro Solutions, LLC
Website
https://longeviti.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Longeviti Neuro Solutions is a Baltimore-based medical device company that develops and sells FDA-cleared sonolucent cranial implants (ClearFit platform) enabling real-time, radiation-free post-operative ultrasound brain imaging for neurosurgeons and hospitals performing complex brain surgery.
Ownership category
akta.pro rank

Longeviti industry classification

Industry
Product category
Neurosurgical Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAJ
3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHADAH
Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Cranial implants
  • Neurosurgical devices
  • Sonolucent implants
  • Post-operative imaging
  • Brain surgery platforms

Where Longeviti is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Longeviti business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales (Implants): Sale of FDA-cleared cranial implants including ClearFit OTS, ClearFit Patient Specific, InvisiShunt, and InvisiLead products. These are一次性医疗器械产品 sold to hospitals and surgical centers for neurosurgical procedures.
  2. Medical Education Services: Provision of medical education including ClearFit imaging workflow training, neurosonography courses, phantom training, and site visits to Centers of Excellence. These services support clinical adoption and proper usage of ClearFit implants.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseOne time/ perpetual licenseClearFit OTS (Off-the-Shelf) implants - standardized sizes

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Longeviti product offering

Product offering

Core offering

Longeviti designs, manufactures, and commercializes FDA-cleared sonolucent cranial implants under its ClearFit® platform, allowing real-time post-operative ultrasound imaging of the brain at the bedside without radiation exposure. The portfolio includes ClearFit OTS off-the-shelf implants, ClearFit Patient Specific custom implants, InvisiShunt and InvisiLead low-profile implants for neurosurgical device accommodation, and AI-powered handheld ultrasound transducers integrated with Clarius and GE systems.

Product overview

Longeviti Neuro Solutions is a neurotechnology company that has developed an innovative platform ecosystem for complex brain surgery. The core offering is the ClearFit® platform, which includes ClearFit® OTS (off-the-shelf) and ClearFit® Patient Specific cranial implants—sonolucent implants that enable real-time post-operative ultrasound imaging of the brain, eliminating the need for radiation-based imaging and enabling bedside monitoring. The platform also includes InvisiShunt® and InvisiLead, which are low-profile cranial implants that integrate seamlessly with the skull for neurosurgical device accommodation. The ClearFit AI™ component powers handheld ultrasound transducers from Clarius and GE, providing AI-enabled imaging capabilities. All products work together to provide comprehensive neurosurgical solutions that return patients to anatomical normalcy while providing functional neurotechnology.

Differentiator

Problem solved

Functional benefit

Brands

  • ClearFit OTS: FDA-cleared off-the-shelf cranial implants that enable real-time ultrasound imaging at the bedside or clinic
  • ClearFit Patient Specific
  • InvisiShunt and InvisiLead
  • ClearFit AI

Products and services

  • ClearFit® OTS (Off-the-Shelf) Cranial Implants

Quantifiable outcome

  • ICD-10-PCS Code: XNR80D9 assigned for Ultrasound Penetrable replacement cranial plate

Companies that use Longeviti

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Longeviti technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature4 records

Longeviti partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered strategic.

  • GE HealthcarestrategicTechnology or IntegrationGE Healthcare provides high-resolution, AI-enabled ultrasound systems that integrate with Longeviti's ClearFit platform, enabling real-time post-operative brain imaging through sonolucent cranial implants.
  • Clarius Mobile HealthstrategicTechnology or IntegrationClarius provides wireless, high-resolution handheld ultrasound systems integrated with Longeviti's ClearFit AI platform for point-of-care brain imaging through cranial implants.
  • Strategic Collaborators (Partners for Advancing Neurosurgery Technology)strategicStrategic or Co-development PartnerLongeviti partners with leading organizations to advance technology in neurosurgery. The company has a network of strategic collaborators including medical technology companies, healthcare institutions, and research organizations (specific partners listed via logos on About page).

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Longeviti competitors and assessment

Company assessment

Direct peers

  • Integra LifeSciences: Integra LifeSciences is a leading neurosurgical and CMF (craniomaxillofacial) implant manufacturer with overlapping cranial plate, dural repair, and neurosurgery portfolios, making it the closest direct competitor to Longeviti in cranial reconstruction hardware.
  • KLS Martin: KLS Martin specializes in CMF surgery implants and distraction devices, directly comparable to Longeviti's patient-specific cranial implant offering, particularly in reconstructive and trauma cranial procedures.

Broad incumbents

  • Stryker: Stryker operates one of the largest neurosurgery, spine, and CMF businesses globally, including cranial implants and instrumentation, and Longeviti's Chair Tim Scannell is the former Stryker President & COO, indicating direct overlap in neurosurgical implant categories.
  • DePuy Synthes (Johnson & Johnson): DePuy Synthes is the dominant CMF and neurosurgical implant franchise within J&J MedTech, offering cranial plates, fixation, and neurosurgical tools that compete head-to-head with Longeviti's ClearFit and InvisiShunt implants in hospital tenders.
  • Medtronic: Medtronic's Neurosurgery business includes shunts and cranial fixation products that overlap with Longeviti's InvisiShunt and ClearFit offerings, and the company competes with Longeviti in the same neurosurgery hospital call points.
  • Aesculap (B. Braun): Aesculap, the surgical division of B. Braun, offers CMF implants and neurosurgical instrumentation, competing with Longeviti across cranial reconstruction and neurosurgical workflows in hospitals globally.
  • Penumbra: Penumbra is a neurovascular and neurosurgery-focused medical device company with overlapping presence in neurosurgical hospital accounts and adjacent technology to Longeviti's neuro-implant and AI workflow platform.

Emerging players

  • Hyperfine: Hyperfine makes the FDA-cleared Swoop portable MRI for point-of-care brain imaging at the bedside, an emerging alternative imaging modality to Longeviti's ClearFit ultrasound-based bedside monitoring in neuro-ICU and post-operative settings.
  • NovaSignal: NovaSignal develops AI-enabled transcranial Doppler ultrasound for automated brain blood flow assessment, overlapping with Longeviti's ClearFit AI platform in point-of-care neurovascular imaging through the skull.
  • Viz.ai: Viz.ai applies AI to neuroimaging workflows for stroke and other neurological conditions, overlapping with Longeviti's ClearFit AI strategy of embedding software intelligence into neurosurgical and neuro-imaging workflows.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Longeviti social profiles

Digital presence

Longeviti financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Longeviti leadership team

Management profile

Number of profiles

Profiles11 records

Longeviti funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Longeviti M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longeviti

What does Longeviti do?

Longeviti designs, manufactures, and commercializes FDA-cleared sonolucent cranial implants under its ClearFit® platform, allowing real-time post-operative ultrasound imaging of the brain at the bedside without radiation exposure. The portfolio includes ClearFit OTS off-the-shelf implants, ClearFit Patient Specific custom implants, InvisiShunt and InvisiLead low-profile implants for neurosurgical device accommodation, and AI-powered handheld ultrasound transducers integrated with Clarius and GE systems.

Is Longeviti a public or private company?

Longeviti is a private company. It is classified as venture growth investor backed and is currently operating.

When was Longeviti founded?

Longeviti was founded in 2016. It employs 51 to 100 people.

Where is Longeviti based?

Longeviti is headquartered in Baltimore, United States, in the North America region.

How does Longeviti make money?

Two revenue lines are on record. Medical Device Sales (Implants) is the primary driver. The others are medical Education Services.

Who are Longeviti's main competitors?

Direct peers on record are Integra LifeSciences and KLS Martin. Broad incumbents are Stryker, DePuy Synthes (Johnson & Johnson), Medtronic, Aesculap (B. Braun) and Penumbra. Emerging players are Hyperfine, NovaSignal and Viz.ai.

Does Longeviti have an API?

No public API is recorded for Longeviti.

What industry is Longeviti in?

Longeviti's product category is Neurosurgical Medical Devices. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts), with a secondary code of HLAHAEAJ, 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Imaging Technology NewsLongeviti Brain Ultrasound InterfaceLongeviti Neuro Solutions launched ClearFit AI, a Brain Ultrasound Interface that utilizes sonolucent cranial implants to enable real-time bedside imaging for neurosurgical care. The platform is designed to reduce reliance on CT and MRI transport by integrating AI-enhanced imaging with existing clinical workflows, though specific benefits depend on future regulatory validation. The technology is currently available exclusively on Clarius Ultrasound units.Business Wire BlogLongeviti Launches ClearFit AI™, a Brain Ultrasound Interface (BUI) to Advance Platform Solutions for Neurological DisordersLongeviti Neuro Solutions announced the launch of ClearFit AI™, a Brain Ultrasound Interface (BUI) platform that combines sonolucent cranial implants, bedside ultrasound imaging, and artificial intelligence to enable real-time post-operative brain visualization at the bedside. The platform, which uses Clarius Ultrasound units for AI-assisted imaging optimization, aims to reduce reliance on CT and MRI transport, decrease radiation exposure for patients, and integrate into existing neuro workflows. The company stated that future clinical, operational, or economic benefits will depend on regulatory review, validation activities, adoption patterns, and real-world implementation.FinancialContent Business PageLongeviti Launches ClearFit AI™, a Brain Ultrasound Interface (BUI) to Advance Platform Solutions for Neurological DisordersLongeviti Neuro Solutions announced the launch of ClearFit AI™, a Brain Ultrasound Interface platform that combines FDA-cleared sonolucent cranial implants with bedside ultrasound imaging and artificial intelligence to enable real-time post-operative brain visualization. The platform is designed to reduce reliance on CT and MRI transport, integrate into existing neurosurgical workflows, and operate exclusively on Clarius Ultrasound units. The company noted that any future clinical, operational, or economic benefits will depend on regulatory review, validation activities, and real-world adoption patterns.Longevity.TechnologyLongevitix launches AI platform to tackle longevity data overloadLongevitix launched an AI-powered clinical intelligence platform to synthesize fragmented longevity data from labs, wearables, and clinical notes. The system uses a five-tier evidence framework and specialist organ-system models, aiming to help physicians deliver continuous preventive care. CEO Effie Arditi expects the model to influence payers within 3-5 years.BioSpaceLongeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of DirectorsLongeviti Neuro Solutions announced the appointment of Robert W. Sharps, CEO and President of T. Rowe Price Group, to its Board of Directors. Sharps brings three decades of leadership experience in global asset management, overseeing more than $1.5 trillion in assets for the investment firm. The appointment is intended to strengthen Longeviti's strategic planning, governance, and partnerships as it scales its neurotechnology platform including the ClearFit AI system.Investing.comT. Rowe Price CEO joins Longeviti Neuro board of directors By Investing.comRobert W. Sharps, CEO and President of T. Rowe Price Group, has been appointed to the Board of Directors of Longeviti Neuro Solutions, a Baltimore-based neurotechnology company. Sharps brings three decades of global asset management experience and will support Longeviti's strategic planning, partnerships, and scaling of operations as the company expands its clinical and commercial initiatives. Separately, T. Rowe Price reported Q4 2025 adjusted diluted EPS of $2.44, narrowly missing the analyst forecast of $2.46, while raising its quarterly dividend to $1.30 per share.GlobeNewswireLongeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of DirectorsLongeviti Neuro Solutions, a Baltimore-based neurotechnology company, announced the appointment of Robert W. Sharps, CEO and President of T. Rowe Price Group, to its Board of Directors. Sharps, who oversees $1.5 trillion in assets as head of one of the world's leading investment firms, brings three decades of leadership experience in global asset management and corporate governance to the role. The appointment is part of Longeviti's effort to strengthen its strategic planning and governance as the company scales its neuro-implant and AI-driven technology platform, including the FDA-cleared ClearFit AI system.GlobeNewswireLongeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of DirectorsLongeviti Neuro Solutions has appointed Robert W. Sharps, CEO and President of T. Rowe Price Group, Inc., to its Board of Directors. Sharps brings three decades of leadership experience in global asset management and corporate governance to the neurotechnology company. The appointment is intended to strengthen Longeviti's strategic planning, governance, and partnerships as it scales its AI-enabled neurotechnology platform including the ClearFit AI system.NasdaqLongeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of DirectorsLongeviti Neuro Solutions appointed Robert W. Sharps, CEO of T. Rowe Price Group, to its Board of Directors to leverage his expertise in global asset management and corporate governance. This strategic addition aims to support Longeviti's clinical initiatives, commercial expansion of its ClearFit AI platform, and long-term therapeutic roadmap.Longevity.TechnologyLongevitix named Catalyst Partner for The Longevity Show 2026Longevitix, a clinical infrastructure platform for longevity medicine, has been named Catalyst Partner for The Longevity Show 2026, which is debuting in London this June. The platform uses a proprietary AI engine with a deterministic Multi-Layer Clinical Safeguard architecture to aggregate patient data from multiple sources and translate it into structured, practitioner-ready clinical recommendations, including automated patient-clinician accountability loops for proactive care continuity. The partnership highlights a broader shift in longevity medicine toward operationalizing preventive care delivery at scale, moving from discovery-focused practice to dependable, measurable clinical workflows.